E Talking With NuLife’s CEO About Transplants And Technology

Introduction

From the company website: NuLife Sciences (NULF)  is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method (“NuLife Technique”) that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs.

We recently had the opportunity to interview NuLife’s CEO, John Hollister.

What is NuLife Sciences all about?

NuLife Sciences is committed to developing and commercializing advances in medical science which have significant benefits for patients. Our first area of focus is in kidney transplant, utilizing the NuLife Technique, which harnesses the potential power of cytokines released from our proprietary process.

How did NuLife determine what services it would provide?

We reviewed a number of variables including the unmet need, potential impact (survival, cost, and QOL), regulatory pathway, competitive environment, and time to commercialization to determine which indication to pursue first.

Are your services patented?

Yes. And, we will be expanding our existing patent portfolio, as well as adding additional patents.

What is the total available market for your services?

If we limit the discussion to kidney transplants, there are roughly 18,000 transplant procedures each year. While we have not established a price for our process, we believe that there is an available market approaching $1B. This does not include any expansion in the number of transplants conducted per year.

Given this market, how much market share is reasonable for NuLife Medical to acquire?

If the NuLife Technique is able to accomplish what we hope, we believe it is reasonable to assume that 90% of kidney transplants will utilize the process within three years of marketing authorization.